A Phase 3 interventional study of low-titer O-group whole blood and 1:1:1 component transfusion in Hemorrhage, Hemorrhagic Shock and Upper Gastrointestinal Bleeding (UGIB), sponsored by Xijing Hospital. Not yet recruiting at 1 site in China. Open to participants aged 10 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-08-19.
Sponsored by Xijing Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This single-center, prospective, randomized controlled trial was approved by the institutional ethics committee and overseen by an independent data and safety monitoring board. It enrolled patients with hemorrhagic shock caused by trauma or major gastrointestinal bleeding. Using a random-number-table method, participants were allocated to three groups: (1) Control group: standard massive transfusion protocol (MTP) with transfusing type-specific blood components in a 1:1:1 ratio. (2) Type-specific whole-blood group: following emergency ABO typing and cross-matching, type-specific whole blood was transfused. (3) Low-titer group O whole-blood group: in the emergency phase, 4 units of low-titer group O whole blood (anti-A/B IgM titer \< 1:64) were infused; after definitive ABO typing, patients were switched to type-specific whole blood. Clinical data were automatically extracted from the electronic medical record system. Primary endpoints were efficacy (28-day survival), timeliness (transfusion waiting time and time to achieve target mean arterial pressure), cost-effectiveness (total blood consumption and transfusion-related expenses), and safety (transfusion-associated adverse events including TRALI and hemolytic reactions).Statistical analyses included Kaplan-Meier survival curves and Cox proportional-hazards regression, adjusting for confounders such as age and disease severity scores. The advantages and disadvantages of each transfusion strategy were evaluated, and an optimized strategy for emergency blood transfusion in hemorrhagic shock was developed. This strategy was peer-reviewed and refined, culminating in a standardized, multidisciplinary, emergency-transfusion protocol.
79 studies on the registry are indexed under Shock, Hemorrhagic; 15 are open to participants now.
This study's planned enrollment of 180 is above the median of 107 across 42 interventional studies indexed under Shock, Hemorrhagic.
Browse Shock, Hemorrhagic studies →Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
Compared within Shock, Hemorrhagic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hemorrhage. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age 10-90 years. Time from onset to hospital admission \< 24 hours.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following the "Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)", implement the massive transfusion protocol (MTP) by transfusing type-specific blood components in a 1:1:1 ratio (red blood cells : plasma : platelets).
Drug: 1:1:1 component transfusion
Administer type-specific whole-blood transfusion in accordance with the "Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)".
Drug: ABO- and Rh-compatible whole blood
During the emergency phase, administer 4 units of low-titer group O whole blood (anti-A/B IgM antibody titer \< 1:64); once the patient's blood type is determined, switch to type-specific whole blood.
Drug: low-titer O-group whole blood
Arm Description: During the emergency phase, administer 4 units of low-titer group O whole blood (anti-A/B IgM antibody titer \< 1:64); once the patient's blood type is determined, switch to type-specific whole blood.
Following the "Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)", implement the massive transfusion protocol (MTP) by transfusing type-specific blood components in a 1:1:1 ratio (red blood cells : plasma : platelets).
Administer type-specific whole-blood transfusion in accordance with the "Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)".
survival rate
Time frame: 24 hours,30 days
Plan to share: Yes — The following de-identified individual participant data (IPD) will be shared via a public repository (Dryad Digital Repository) no later than 12 months after the primary results publication. Participant-level baseline characteristics Age, sex, body-mass index, Injury Severity Score (ISS), baseline hemoglobin, vital signs on arrival, coagulation parameters (INR, platelet count, fibrinogen), lactate. Intervention allocation and delivery data • Randomization group, actual blood products transfused (type, volume, sequence, total units), time from randomization to first transfusion. Primary and secondary outcomes (28-day follow-up) Vital status at 28 days (alive/dead), date and cause of death if applicable. Time to achieve mean arterial pressure ≥ 65 mmHg, total blood products and crystalloids within 24 h, incidence and date of TRALI, TACO, acute hemolytic reactions, ICU length of stay, hospital length of stay, total transfusion-related costs. Safety events All-grade and grade ≥3 ad
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: January 2026-January 2028
Access criteria: 1. The IPD and supporting information will be accessible to the following parties: Principal Investigator (PI) and Study Team: The PI and designated members of the study team, including co-investigators, biostatisticians, and data managers, will have access to the IPD and supporting information for the purpose of conducting the study, analyzing data, and preparing reports. Independent Data and Safety Monitoring Board (DSMB): The DSMB will have access to the IPD and supporting information to monitor the safety and efficacy of the study interventions and to provide recommendations based on interim analyses. Ethics Committees: These committees may request access to the IPD and supporting information to ensure compliance with ethical standards and to review the study protocol and conduct. Sponsor and Sponsor's Representatives: The sponsor of the study and their designated representatives may have access to the IPD and supporting information for oversight and monitoring of the study
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Jun 2027, 21 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.